Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45664 | 1.00 | ALDH1A1 (0.34) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL28102949 | 0.95 | BACE1 (0.36) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| Carbimide SCHEMBL28226102 | 0.94 | ALDH1A1 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL4965543 | 0.91 | ALDH1A1 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL5578691 | 0.91 | ALDH1A1 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL28349186 | 0.91 | ALDH1A1 (0.31) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL22650155 | 0.90 | ALDH1A1 (0.37) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL28090625 | 0.88 | — | — | |
| SCHEMBL16552323 | 0.88 | HTR1A (0.33) | LMNAMGLL | |
| SCHEMBL9892471 | 0.88 | HTR1A (0.33) | LMNAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | BIO SYNTHESIS INC (US) | 2025-12-25 | — | — | US | claimed |
| WO-2024227424-A9 | ANTIGEN-BINDING PROTEIN FOR HCLDN6 AND USE THEREOF | 泰诚思(上海)生物医药有限公司 | 2025-02-20 | — | — | WO | claimed |
| WO-2024227426-A1 | ANTIGEN-BINDING PROTEIN FOR HROR1 AND USE THEREOF | 泰诚思(上海)生物医药有限公司 | 2024-11-07 | — | — | WO | claimed |
| WO-2024227424-A1 | ANTIGEN-BINDING PROTEIN FOR HCLDN6 AND USE THEREOF | 泰诚思(上海)生物医药有限公司 | 2024-11-07 | — | — | WO | claimed |
| US-12121527-B2 | Anthracycline-based antibody drug conjugates having high in vivo tolerability | NBE-THERAPEUTICS AG (CH) | 2024-10-22 | — | — | US | claimed |
| US-20240150712-A1 | ARTIFICIAL TARGET FOR ANTIGEN-SPECIFIC ACTIVATION AND EXPANSION OF CAR T CELLS | MILTENYI BIOTEC B.V. & CO KG (DE) | 2024-05-09 | — | — | US | claimed |
| US-20230285579-A1 | NUCLEIC ACID LIGAND CONJUGATES AND USE THEREOF FOR DELIVERY TO CELLS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-09-14 | — | — | US | claimed |
| US-11332880-B2 | Modifying natural feathers for use in sporting goods | DURABIRD (US) | 2022-05-17 | — | — | US | claimed |
| US-20210023103-A1 | ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITY | NBE-THERAPEUTICS AG (CH) | 2021-01-28 | — | — | US | claimed |
| US-10758556-B2 | Anthracycline-based antibody drug conjugates having high in vivo tolerability | NBE-THERAPEUTICS AG (CH) | 2020-09-01 | — | — | US | claimed |
| US-20080311674-A1 | METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS | MONOGRAM BIOSCIENCES, INC. (US) | 2008-12-18 | — | — | US | claimed |
| US-20080199903-A1 | Biological indicator | STERIS INC. (US) | 2008-08-21 | — | — | US | claimed |
| EP-1886143-A1 | BIOLOGICAL INDICATOR | Steris, Inc. (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2007046865-A1 | BIOLOGICAL INDICATOR | STERIS, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20060269983-A1 | Biological indicator | AMERICAN STERILIZER COMPANY | 2006-11-30 | — | — | US | claimed |
| US-20060134694-A1 | Methods of protein profiling by thiolation | INTEL CORPORATION (US) | 2006-06-22 | — | — | US | claimed |
| US-20030013126-A1 | Methods and compositions for analyzing proteins | MONOGRAM BIOSCIENCES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020197649-A1 | Catalytic amplification of multiplexed assay signals | MONOGRAM BIOSCIENCES, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002097112-A2 | CATALYTIC AMPLIFICATION OF MULTIPLEXED ASSAY SIGNALS | ACLARA BIOSCIENCES, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020132990-A1 | Bioengineered vehicles for targeted nucleic acid delivery | DANA-FARBER CANCER INSTITUTE, INC. | 2002-09-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | RNMT, ADAR, RNGTT | ALDH1A1 4823/4885CYP1A2 4877/4885HPGD 4863/4885 |
| US-12121527-B2 | Anthracycline-based antibody drug conjugates having high in vivo tolerability | FCGR2A, FCGR3B, FCGR1A | ALDH1A1 191/4885CYP1A2 640/4885HPGD 2275/4885 |
| US-20210023103-A1 | ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITY | FCGR2A, FCGR3B, FCGR1A | ALDH1A1 191/4885CYP1A2 640/4885HPGD 2275/4885 |
| US-10758556-B2 | Anthracycline-based antibody drug conjugates having high in vivo tolerability | FCGR2A, FCGR3B, FCGR1A | ALDH1A1 191/4885CYP1A2 640/4885HPGD 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.